Recent developments in Targeted Radionuclide Therapy (TRT) and novel therapeutic radiopharmaceuticals have reinvigorated interest in the field and establishment of the TRT Working Group. Two radiopharmaceuticals, $^{131}$I-tositumomab (Bexxar) and $^{90}$Y-ibritumomab tiuxetan (Zevalin), have been approved by the Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Building on the prior success of $^{89}$Sr- and $^{153}$Sm-based therapies, $^{223}$RaCl$_2$ (Xofigo) was tested in clinical trials and shown to improve survival for men with bone metastases from castration-resistant prostate cancer and has since been approved by FDA for this indication. $^{177}$Lu-DOTATATE (Lutathera) has been approved for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Recently, $^{131}$I-MIBG has been approved for treatment of pheochromocytoma or paraganglioma.

The TRT WG was organized to bring together stakeholders from multiple disciplines, including physicians, basic scientists and clinical trial organizations, to provide a forum for free discussion of ideas regarding the development and use of radionuclide therapies.

**Goals**

1. Networking and discussion of new advances in the TRT field;
2. Generation of ideas and establishment of best practices for clinical trials evaluating TRT.
Current Chairperson(s)

☐ Dr. Katherine Zukotynski, MD. (McMaster University
   katherine.zukotynski@utoronto.ca)

☐ Dr. Frank Lin, MD. (NCI, frank.lin2@nih.gov)

Teleconference Schedule

☐ The TRT Working group meets virtually via the WebEx platform once a month – every 1st Wednesday at 5pm ET.

☐ The group membership is approximately 100.

Activities and accomplishments

☐ Exchange of significant information and resources.
   Planning workshops

Interested in becoming a member of the TRT Working Group?

☐ Please Contact the Working Group Coordinator:

Jacek Capala, PhD
Radiation Research Program
National Cancer Institute
Division of Cancer Treatment & Diagnosis
Tel: 240-276-5706
Email: jacekc.capala@nih.gov